Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study - Pipe, S W; Shima, M; Lehle, M (2019)
. Doi: 10.1016/S2352-3026(19)30054-7